Akorn estimates it overstated '14 financials by $35M

Last April, Illinois-based Akorn Pharmaceuticals ($AKRX) told shareholders it had likely overstated its financial results for the last three quarters of 2014--an announcement that sent shares spiraling and triggered investor lawsuits. Now, the company has an update: It estimates its errors resulted in an overstatement of $35 million for that year, though it's still investigating. And in the meantime, it's hired a new accounting firm to get things in order before May 9, 2016--the Nasdaq's compliance deadline. Release | More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…